WO2014102815A1 - Improved process for preparation of vildagliptin - Google Patents

Improved process for preparation of vildagliptin Download PDF

Info

Publication number
WO2014102815A1
WO2014102815A1 PCT/IN2013/000787 IN2013000787W WO2014102815A1 WO 2014102815 A1 WO2014102815 A1 WO 2014102815A1 IN 2013000787 W IN2013000787 W IN 2013000787W WO 2014102815 A1 WO2014102815 A1 WO 2014102815A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
vildagliptin
solvent
reaction mass
Prior art date
Application number
PCT/IN2013/000787
Other languages
French (fr)
Inventor
Shekhar Bhaskar Bhirud
Kumar Hari Bhushan
Amit Anant THANEDAR
Changdev Namdev Raut
Prem Chand
Original Assignee
Glenmark Pharmaceuticals Limited; Glenmark Generics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Limited; Glenmark Generics Limited filed Critical Glenmark Pharmaceuticals Limited; Glenmark Generics Limited
Publication of WO2014102815A1 publication Critical patent/WO2014102815A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • the present invention relates to an improved process for the preparation of vildagliptin.
  • Vildagliptin is a dipeptidyl peptidase IV (DPP-IV) inhibitor and chemically known as (S)-l-[2- (3-hydroxyadamantan-l-ylamino) acetyl] pyrrolidine-2-carbonitrile and is represented by compound of Formula I.
  • DPP-IV dipeptidyl peptidase IV
  • (S) -Vildagliptin is currently marketed in the European Union under the trade name GALVUS®, which is indicated for type-2 diabetes mellitus, as tablets in the dosage strengths of 50 mg and 100 mg.
  • European patent EP 1137635 Bl ('635 patent) describes process for the preparation of vildagliptin.
  • nitrile solvent in the preparation of compound of formula IV has significant advantages in getting easily filterable compound of formula IV with high purity, which leads to vildagliptin with high purity for pharmaceutical use.
  • a solvent other than nitrile solvent is used then there is formation of sticky mass of compound of formula IV, which is not easily filterable and hence not a commercially viable process.
  • the present invention provides a process which is simple, ecofriendly, inexpensive, reproducible, robust and well suited on commercial scale.
  • Formula I comprising: a) reacting a compound of Formula VI
  • step a) the reaction of a compound of formula VI, with a compound of formula V > is carried out in presence of a nitrile solvent.
  • the nitrile solvent may be selected from the group consisting of acetonitrile, propionitrile, butyronitrile, isobutyronitrile, benzonitrile and the like. Preferably, acetonitrile.
  • step a) the reaction of a compound of formula VI, with a compound of formula V, may be carried out in presence or absence of a base.
  • the base may be selected from an inorganic base or organic base.
  • the inorganic base may be selected from alkali metal or alkaline earth metal carbonates or bicarbonates such as sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, alkali metal or alkaline earth metal hydroxide, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, alkali metal alkoxide such as sodium methoxide, potassium methoxide and the like.
  • alkali metal or alkaline earth metal carbonates or bicarbonates such as sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, alkali metal or alkaline earth metal hydroxide, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, alkali metal alkoxide such as sodium methoxide, potassium methoxide and the like.
  • potassium bicarbonate Preferably, potassium bicarbonate.
  • the organic base may be selected from the group consisting of organic amines such as triethylamine, diisopropylethylamine, ⁇ , ⁇ -dimethylaniline, 4-Bromo-N,N-dimethy]aniline, pyridine, 2-bromopyridine, 3-bromopyridine, 4-bromopyridine, 4-dimethylaminopyridine, Di- tert butyl pyridine, 2,6-Di-tert-butyl-4-metbylpyridine, Quinoline, tri-n-butylamine, N- methylmorpholine, 2,6-Lutidine, imidazole, l,5-diazabicyclo[4t3.0]non-5-ene, 1,8- diazabicyclo[5.4.0]undec-7-ene, l,4-diazabicyclo[2.2.2]octane (DABCO), and the like and bases having pKa value 2.5 to 12.
  • organic amines
  • step a) the reaction of a compound of formula VI, with a compound of formula V, may be carried out in presence of an acid scavenger.
  • the acid scavenger is a substance that scavenges the acid formed in the reaction for example alkali or alkaline earth metal salt of acids such as sodium acetate, sodium hexanoate and the like.
  • the dehydrating agent may be selected from the group consisting of phosphorous oxychloride (POCI3), Vilsmeier reagent (a mixture of dimethylformamide (DMF) and POCI3), cyanuric acid halide, trifluroacetic anhydride, Gold reagent (prepared from cyanuric chloride and DMF), mixture of DMF and triphosgene, mixture of diethylformamide (DEF) and POCl 3 , mixture of DMF and thionyl chloride (SOCl 2 ), mixture of DMF and oxalyl chloride and the like.
  • POCl phosphorous oxychloride
  • SOCl 2 mixture of DMF and oxalyl chloride and the like.
  • Vilsmeier reagent a mixture of dimethylformamide (DMF) and POCI3
  • cyanuric acid halide trifluroacetic anhydride
  • Gold reagent prepared from cyanuric chloride and DMF
  • DMF die
  • reaction of compound of formula IV with a dehydrating agent may be carried out with or without a solvent.
  • the solvent may be selected form the group consisting of halogenated hydrocarbon, esters and ether.
  • the halogenated hydrocarbon may be selected from the group consisting of ethylene dichloride, methylene dichloride and the like.
  • the ester solvent may be selected form the group consisting of ethyl acetate, butyl acetate and the like.
  • the ether solvent may be selected form the group consisting of tetrahydrofuran, tetrahydropyran and the like.
  • the reaction of compound of formula IV with a dehydrating agent may be carried out in the temperature of about -5° C to about 40° C, preferably at about 0° C to 20° C more preferably at about 15° C to 20° C.
  • the compound of formula IV obtained may be isolated from the reaction mixture by crystallization or slurrying in an organic solvent.
  • the compound of formula IV is isolated from the reaction mixture by slurrying in presence of nitrile solvent, ester solvent or a mixture of nitrile solvent and ester solvent.
  • nitrile solvent for example a mixture of acetonitrile and ethyl acetate may be used for isolating the compound of formula IV.
  • the compound of formula IV is isolated from the reaction mixture by crystallizing the compound of formula IV from the reaction mixture by removal of solvent the reaction mixture or addition of an anti-solvent to the reaction mixture. After completion of reaction the pH of the reaction mixture is adjusted in the range of about 6-8 by use of a base.
  • the base may be selected from alkali metal or alkaline earth metal hydroxide, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, alkali metal alkoxide such as sodium methoxide, potassium methoxide, alkali metal or alkaline earth metal carbonates or bicarbonates such as sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate and the like.
  • alkali metal or alkaline earth metal hydroxide such as sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide
  • alkali metal alkoxide such as sodium methoxide, potassium methoxide
  • alkali metal or alkaline earth metal carbonates or bicarbonates such as sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate and the like.
  • the compound of formula III obtained may be isolated from the reaction mixture by crystallization or slurrying in an organic solvent.
  • the compound of formula III is isolated from the reaction mixture by slurrying in presence of an ether solvent such as methyl tert butyl ether.
  • the compound of formula III is isolated from the reaction mixture by slurrying in presence of a mixture of an alcoholic solvent and ether solvent.
  • a mixture of isopropyl alcohol and methyl tert butyl ether may be used for isolating the compound of formula III.
  • the compound of formula III is isolated from the reaction mixture by crystallizing the compound of formula III from the reaction mixture by removal of solvent the reaction mixture or addition of an anti-solvent to the reaction mixture.
  • step c) the compound of formula III is reacted with compound of formula II.
  • reaction of compound of formula III with a compound of formula II may be carried out in presence of a base.
  • the base may be selected from an inorganic base or organic base.
  • the inorganic base may be selected from alkali metal or alkaline earth metal carbonates or bicarbonates such as sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, alkali metal or alkaline earth metal hydroxide, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, alkali metal alkoxide such as sodium methoxide, potassium methoxide and the like.
  • potassium carbonate is potassium carbonate. .
  • the organic base may be selected from the group consisting of organic amines such as triethylamine, diisopropylethylamine, N,N-dimethylaniline, 4-Bromo-N,N-dimethylaniline, pyridine, 2-bromopyridine, 3-bromopyridine, 4-bromopyridine, 4-dimethylaminopyridine, Di- tert butyl pyridine, 2,6-Di-tert-butyl-4-methylpyridine, Quinoline, tri-n-butylamine, N- methylmorpholine, 2,6-Lutidine, imidazole, l,5-diazabicyclo[4.3.0]non-5-ene, 1 ,8- diazabicyclo[5.4.0]undec-7-ene, l,4-diazabicyclo[2.2.2]octane (DABCO), and the like and bases having pKa value 2.5 to 12.
  • organic amines such as trie
  • reaction of compound of formula III with a compound of formula II may be carried out in presence of a solvent.
  • the solvent may be selected from the group consisting of nitrile, ester and alcohols.
  • nitriles such as acetonitrile.
  • reaction of compound of formula III with a compound of formula II may be carried out in the temperature range of about 30°C to about 100 °C, preferably about 40° C to 80° C, more preferably about 70° C to 75° C.
  • the present invention provides a process for preparation of vildagliptin, compound of formula I, by reaction of compound of formula III with a compound of formula II, wherein compound of formula III was added in lot wise, preferably in four lots at about 40° C to 80° C, preferably at about 70° C to 75° C to control impurity D.
  • the present invention provides a process for preparation of vildagliptin, compound of formula I, wherein compound of formula III and compound of formula IV may be used in-situ.
  • the present invention provides a process for preparation of vildagliptin, compound of formula I, comprising: a) reacting a compound of formula VI with a compound of formula V in the presence of a nitrile solvent to form a compound of formula IV; b) purifying the compound of formula IV with nitrile solvent, ester solvent or mixture thereof; c) reacting the compound of formula IV with a dehydrating agent to form a compound of formula III; d) purifying the compound of formula III with alcohol solvent, ether solvent or mixture thereof; and e) reacting the compound of formula III with a compound of formula II to form a compound of formula I.
  • the nitrile solvent, ester solvent, ether solvent and alcohol solvent are as discussed supra.
  • the present invention provides a process for preparation of vildagliptin, compound of formula I, having impurity G and/ or impurity H less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC, obtained by process as described above.
  • the compound of formula I obtained may be isolated from the reaction mixture in a solvent selected from the group consisting of esters, ketones, alcohols or mixtures thereof by slurrying or recrystallization.
  • the esters may be selected form the group consisting of ethyl acetate, propyl acetate, butyl acetate and the like.
  • the ketones may be selected form the group consisting of acetone, methyl ethyl ketone and the like.
  • the alcohols may be selected from the group consisting of methanol, ethanol, propanol, isopropanol and the like.
  • the compound of formula I is isolated from the reaction mixture by slurrying in ethyl acetate. In one embodiment the compound of formula I is isolated from the reaction mixture by slurrying in methyl ethyl ketone.
  • the compound of formula I is isolated from the reaction mixture by recrystallization in methyl ethyl ketone.
  • the present invention provides a process for purification of vildagliptin, compound of formula I by a process comprising recrystallizing in an alcoholic solvent system.
  • the present invention provides a process for purification of vildagliptin, compound of formula I by a process comprising recrystallizing in isopropyl alcohol.
  • the present invention provides vildagliptin obtained by the processes herein described, having purity more than about 99.6% as measured by High Performance Liquid Chromatography (HPLC).
  • HPLC High Performance Liquid Chromatography
  • the present invention provides vildagliptin having compound of formula IV less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC.
  • the present invention provides vildagliptin having compound of formula III less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC. In one embodiment, the present invention provides vildagliptin having compound of formula II less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC.
  • the present invention provides vildagliptin having impurity D less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC.
  • the present invention provides vildagliptin having impurity E or its isomer or its salt less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC.
  • the present invention provides vildagliptin having impurity F or its isomer or its salt less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC.
  • the present invention provides S-vildagliptin having R-vildagliptin impurity is present less than 0.15% w/w relative to the amount of S-vildagliptin as determined by chiral HPLC.
  • the present invention provides compound of formula III and/or vildagliptin free of impurity G or its isomer or its salt as determined by HPLC.
  • the present invention provides compound of formula IV, compound of formula III, and/or vildagliptin free of impurity H or its isomer or its salt as determined by HPLC.
  • the present invention provides vildagliptin, where is one or more of compounds of formula II, III, IV, impurity D, impurity E or impurity F are present less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC and R-vildagliptin is present less than 0.15% w/w relative to the amount of vildagliptin as determined by chiral- HPLC.
  • the present invention provides vildagliptin, having compound of formula III (genotoxic impurity) below detection limit, preferably below 15 parts per million (ppm).
  • the present invention provides vildagliptin, having compound of formula IV (genotoxic impurity) below detection limit, preferably below 15 parts per million (ppm). In one embodiment the present invention provides vildagliptin, compound of formula I having bulk density of 0.54 g/cc.
  • the present invention provides pharmaceutical compositions comprising vildagliptin obtained by the processes herein described, having a D90 particle size of about 375 microns, D 50 particle size of about 207 microns and D 10 particle size of about 37 microns.
  • the present invention provides pharmaceutical compositions comprising micronized vildagliptin obtained by the processes herein described, having a D90 particle size of about 78 microns, D 50 particle size of about 17 microns and Dio particle size of about 4 microns.
  • the present invention provides a process for the preparation of a compound of Formula IV,
  • Formula IV comprising: a) reacting a compound of Formula VI
  • the ester solvent may be selected from the group consisting of methyl acetate, ethyl acetate, n- butyl acetate, isobutyl acetate, sec-butyl acetate, isopropyl acetate and the like and mixtures thereof.
  • the halogenated hydrocarbons solvent may be selected from methylene chloride (MDC), ethylene chloride (EDC) and like.
  • Ether solvent may be selected from tetrahydrofuran, tetrahydropyran and the like.
  • Example 2 Preparation of (S)-l-(2-chloroacetyl) pyrrolidine-2-carboxamide, compound of Formula IV.
  • lOOgm L-prolinamide 1000ml MDC and 290.16gm K 2 C0 3 were charged.
  • the reaction mass was stirred, cooled to about 10-20°C and 108.8gm of chloroacetyl chloride was added.
  • Temperature of reaction mass was raised to about RT, stirred for about one hour, filtered, washed with MDC and concentrated under vacuum. 300ml ethyl acetate was added to reaction mass, stirred at about 50-55 °C, cooled to about 0-5 °C.
  • the reaction mass was filtered, washed with ethyl acetate and dried under vacuum and product isolated as a solid lOOgm. (HPLC purity >97%)
  • Example 4 Preparation of (S)-l-(2-chIoroacetyl) pyrroUdine-2-carboxamide, compound of Formula IV.
  • lOOgm L-prolinamide, 1000ml THF and 166gm sodium.2-ethyl hexanoate were charged.
  • the reaction mass was stirred, cooled to about 10-15°C and 108.8gm of chloroacetyl chloride was added. Temperature of reaction mass was raised to about T, stirred for about one hour and cooled to about 0-5 °C.
  • the reaction mass was filtered, washed with THF and dried under vacuum and product isolated as a solid 135gm. (HPLC purity >97%)
  • Example 5 Preparation of (S)-l-(2-chloroacetyl) pyrrolidine-2-carbonitrile, compound of Formula III.
  • Example 9 Preparation of (S)-l-(2-chloroacetyl) pyrrolidine-2-carbonitrile, compound of Formula III.
  • lOOgm compound IV and 1200 ml of MDC were charged.
  • DMF (76.6gm) was charged in the flask.
  • the reaction mass was cooled to 15°C.
  • Phosphorus oxychloride was added through addition funnel at 15-20°C and the reaction mass was stirred for 90 min. Cool the reaction mass to 5-10°C. The reaction mass was cooled to 5-10°C. The reaction mass was cooled to 5-10°C. The reaction mass was quenched by adding water. The aqueous layer was separated and extracted with MDC.
  • the MDC layers were combined and the pH adjusted to -7-8 by using potassium carbonate solution.
  • the aqueous layer was separated.
  • the MDC layer was concentrated under vacuum (40-45°C).
  • the residue was degassed.
  • Methyl tert butyl ether was charged to the residue.
  • the precipitated solid was stirred at 0-5°C for .120 min.
  • the solid was filtered and washed with cold methyl tert butyl ether and suck dried.
  • the solid was dried under vacuum at 30-35°C. 58-62gm of solid was obtained (Yield 65-68%, HPLC purity > 98% and other isomer less than 0.15%).
  • Example 11 Preparation of (S)-l-(2-chloroacetyI) pyrrolidine-2-carbonitrile, compound of Formula III.
  • Example 12 Preparation of vildagliptin, compound of Formula I.
  • (lOOgm) of l-amino-3-adamantol in 1000ml of acetonitrile were charged.
  • 239.8gm of potassium carbonate was charged to the above flask.
  • the reaction mass was heated to 82-85°C.
  • the compound of formula III (4x25gm), was charged after 60-90 min intervals.
  • the reaction mass was cooled to 65-70°C.
  • the reaction mass was filtered and the solid was washed with 500ml acetonitrile and suck dried.
  • the acetonitrile was distilled out from filtrate under vacuum at 50-55°C.
  • Methyl ethyl ketone was charged to the residue and the slurry stirred at 50-55°C for 30-45 minutes. The slurry was cooled to 20-30°C and stirred for 60-90 minutes. The solid was filtered and washed with methyl ethyl ketone and suck dried. The wet cake was suspended in IPA and heated to 80-85 °C to get a clear solution. The clear solution was charcoalised and filtered through hyflo. The filtrate was ⁇ distilled out under vacuum to get final volume to 5Volume. The reaction mass was cooled to -5 to 5°C and stirred for 60-90 minutes. The solid was filtered and washed with IPA and suck dried. The solid was dried under vacuum at 50-55°C. 105 to 120gm of solid was obtained (yield 59-68%, HPLC purity >98%)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to process for the preparation of vildagliptin.

Description

IMPROVED PROCESS FOR PREPARATION OF VILDAGLIPTIN
PRIORITY
This application claims the benefit to Indian Provisional Application No. 3622/MUM/2012, filed on December 26, 2012, the contents of which are incorporated by reference herein.
FIELD OF THE INVENTION
The present invention relates to an improved process for the preparation of vildagliptin. BACKGROUND OF THE INVENTION
Vildagliptin is a dipeptidyl peptidase IV (DPP-IV) inhibitor and chemically known as (S)-l-[2- (3-hydroxyadamantan-l-ylamino) acetyl] pyrrolidine-2-carbonitrile and is represented by compound of Formula I.
Figure imgf000002_0001
Formula I
(S) -Vildagliptin is currently marketed in the European Union under the trade name GALVUS®, which is indicated for type-2 diabetes mellitus, as tablets in the dosage strengths of 50 mg and 100 mg.
European patent EP 1137635 Bl ('635 patent) describes process for the preparation of vildagliptin.
United States Patent No. 7,375,238 and PCT Patent Publications WO2008/084383, WO2010/022690, WO2011/012322, WO 2011/101861, WO2011/042765, WO2012/004210 and WO2012/022994 describe processes for vildagliptin or salt thereof.
In light of the evolving and more rigorous requirements demanded of drug manufacturers and the prevailing disadvantages present with the prior art, there is a need for an improved process for the preparation of vildagliptin and its intermediates, which circumvents the likely formation of isomeric and other process-related impurities; while ensuring a target vildagliptin product with optimum yield and purity.
Surprisingly, it has been found that use of nitrile solvent in the preparation of compound of formula IV has significant advantages in getting easily filterable compound of formula IV with high purity, which leads to vildagliptin with high purity for pharmaceutical use. There is disadvantage in reported process that if a solvent other than nitrile solvent is used then there is formation of sticky mass of compound of formula IV, which is not easily filterable and hence not a commercially viable process. The present invention provides a process which is simple, ecofriendly, inexpensive, reproducible, robust and well suited on commercial scale.
SUMMARY OF THE INVENTION
A process for the preparation of vildagliptin, a compound of Formula I,
Figure imgf000003_0001
Formula I comprising: a) reacting a compound of Formula VI
Figure imgf000003_0002
Formula VI with a compound of formula V,
Figure imgf000004_0001
Formula V
in the presence of a nitrile solvent to form a compound of formula IV;
Figure imgf000004_0002
Formula IV
b) reacting the compound of formula IV with a dehydrating agent to form a compound of formula III,
Figure imgf000004_0003
Formula III
c) reacting the compound of formula III with a compound of formula II,
Figure imgf000004_0004
to form a compound of formula I. DETAILED DESCRIPTION OF INVENTION
A process for the preparation of vildagliptin, a compound of Formula I,
Figure imgf000005_0001
Formula I
comprising: a) reacting a compound of Formula VI
Figure imgf000005_0002
Formula VI
with a compound of formula V,
Figure imgf000005_0003
Formula V
the presence of a nitrile solvent to form a compound of formula IV;
Figure imgf000005_0004
Formula IV
b) reacting the compound of formula IV with a dehydrating agent to form a compound of formula III,
Figure imgf000006_0001
Formula III c) reacting the compound of formula III with a compound of formula II,
Figure imgf000006_0002
Formula II to form a compound of formula I.
In step a), the reaction of a compound of formula VI, with a compound of formula V> is carried out in presence of a nitrile solvent. The nitrile solvent may be selected from the group consisting of acetonitrile, propionitrile, butyronitrile, isobutyronitrile, benzonitrile and the like. Preferably, acetonitrile.
In step a), the reaction of a compound of formula VI, with a compound of formula V, may be carried out in presence or absence of a base.
The base may be selected from an inorganic base or organic base.
The inorganic base may be selected from alkali metal or alkaline earth metal carbonates or bicarbonates such as sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, alkali metal or alkaline earth metal hydroxide, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, alkali metal alkoxide such as sodium methoxide, potassium methoxide and the like. Preferably, potassium bicarbonate.
■ The organic base may be selected from the group consisting of organic amines such as triethylamine, diisopropylethylamine, Ν,Ν-dimethylaniline, 4-Bromo-N,N-dimethy]aniline, pyridine, 2-bromopyridine, 3-bromopyridine, 4-bromopyridine, 4-dimethylaminopyridine, Di- tert butyl pyridine, 2,6-Di-tert-butyl-4-metbylpyridine, Quinoline, tri-n-butylamine, N- methylmorpholine, 2,6-Lutidine, imidazole, l,5-diazabicyclo[4t3.0]non-5-ene, 1,8- diazabicyclo[5.4.0]undec-7-ene, l,4-diazabicyclo[2.2.2]octane (DABCO), and the like and bases having pKa value 2.5 to 12.
In step a), the reaction of a compound of formula VI, with a compound of formula V, may be carried out in presence of an acid scavenger. The acid scavenger is a substance that scavenges the acid formed in the reaction for example alkali or alkaline earth metal salt of acids such as sodium acetate, sodium hexanoate and the like.
In step b), the dehydrating agent may be selected from the group consisting of phosphorous oxychloride (POCI3), Vilsmeier reagent (a mixture of dimethylformamide (DMF) and POCI3), cyanuric acid halide, trifluroacetic anhydride, Gold reagent (prepared from cyanuric chloride and DMF), mixture of DMF and triphosgene, mixture of diethylformamide (DEF) and POCl3, mixture of DMF and thionyl chloride (SOCl2), mixture of DMF and oxalyl chloride and the like. Preferably, Vilsmeier reagent.
The reaction of compound of formula IV with a dehydrating agent may be carried out with or without a solvent.
The solvent may be selected form the group consisting of halogenated hydrocarbon, esters and ether.
The halogenated hydrocarbon may be selected from the group consisting of ethylene dichloride, methylene dichloride and the like. The ester solvent may be selected form the group consisting of ethyl acetate, butyl acetate and the like.
The ether solvent may be selected form the group consisting of tetrahydrofuran, tetrahydropyran and the like.
The reaction of compound of formula IV with a dehydrating agent may be carried out in the temperature of about -5° C to about 40° C, preferably at about 0° C to 20° C more preferably at about 15° C to 20° C. In one embodiment the compound of formula IV obtained may be isolated from the reaction mixture by crystallization or slurrying in an organic solvent.
In one embodiment the compound of formula IV is isolated from the reaction mixture by slurrying in presence of nitrile solvent, ester solvent or a mixture of nitrile solvent and ester solvent. For example a mixture of acetonitrile and ethyl acetate may be used for isolating the compound of formula IV.
In one embodiment the compound of formula IV is isolated from the reaction mixture by crystallizing the compound of formula IV from the reaction mixture by removal of solvent the reaction mixture or addition of an anti-solvent to the reaction mixture. After completion of reaction the pH of the reaction mixture is adjusted in the range of about 6-8 by use of a base.
The base may be selected from alkali metal or alkaline earth metal hydroxide, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, alkali metal alkoxide such as sodium methoxide, potassium methoxide, alkali metal or alkaline earth metal carbonates or bicarbonates such as sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate and the like.
The compound of formula III obtained may be isolated from the reaction mixture by crystallization or slurrying in an organic solvent.
In one embodiment the compound of formula III is isolated from the reaction mixture by slurrying in presence of an ether solvent such as methyl tert butyl ether.
In one embodiment the compound of formula III is isolated from the reaction mixture by slurrying in presence of a mixture of an alcoholic solvent and ether solvent. For example a mixture of isopropyl alcohol and methyl tert butyl ether may be used for isolating the compound of formula III. In one embodiment the compound of formula III is isolated from the reaction mixture by crystallizing the compound of formula III from the reaction mixture by removal of solvent the reaction mixture or addition of an anti-solvent to the reaction mixture. In step c) the compound of formula III is reacted with compound of formula II.
The reaction of compound of formula III with a compound of formula II may be carried out in presence of a base.
The base may be selected from an inorganic base or organic base. The inorganic base may be selected from alkali metal or alkaline earth metal carbonates or bicarbonates such as sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, alkali metal or alkaline earth metal hydroxide, such as sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, alkali metal alkoxide such as sodium methoxide, potassium methoxide and the like. Preferably, potassium carbonate. . The organic base may be selected from the group consisting of organic amines such as triethylamine, diisopropylethylamine, N,N-dimethylaniline, 4-Bromo-N,N-dimethylaniline, pyridine, 2-bromopyridine, 3-bromopyridine, 4-bromopyridine, 4-dimethylaminopyridine, Di- tert butyl pyridine, 2,6-Di-tert-butyl-4-methylpyridine, Quinoline, tri-n-butylamine, N- methylmorpholine, 2,6-Lutidine, imidazole, l,5-diazabicyclo[4.3.0]non-5-ene, 1 ,8- diazabicyclo[5.4.0]undec-7-ene, l,4-diazabicyclo[2.2.2]octane (DABCO), and the like and bases having pKa value 2.5 to 12.
The reaction of compound of formula III with a compound of formula II may be carried out in presence of a solvent.
The solvent may be selected from the group consisting of nitrile, ester and alcohols. Preferably nitriles such as acetonitrile.
The reaction of compound of formula III with a compound of formula II may be carried out in the temperature range of about 30°C to about 100 °C, preferably about 40° C to 80° C, more preferably about 70° C to 75° C.
In one embodiment the present invention provides a process for preparation of vildagliptin, compound of formula I, by reaction of compound of formula III with a compound of formula II, wherein compound of formula III was added in lot wise, preferably in four lots at about 40° C to 80° C, preferably at about 70° C to 75° C to control impurity D. In one embodiment the present invention provides a process for preparation of vildagliptin, compound of formula I, wherein compound of formula III and compound of formula IV may be used in-situ.
In one embodiment the present invention provides a process for preparation of vildagliptin, compound of formula I, comprising: a) reacting a compound of formula VI with a compound of formula V in the presence of a nitrile solvent to form a compound of formula IV; b) purifying the compound of formula IV with nitrile solvent, ester solvent or mixture thereof; c) reacting the compound of formula IV with a dehydrating agent to form a compound of formula III; d) purifying the compound of formula III with alcohol solvent, ether solvent or mixture thereof; and e) reacting the compound of formula III with a compound of formula II to form a compound of formula I. The nitrile solvent, ester solvent, ether solvent and alcohol solvent are as discussed supra.
In one embodiment the present invention provides a process for preparation of vildagliptin, compound of formula I, having impurity G and/ or impurity H less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC, obtained by process as described above.
The compound of formula I obtained may be isolated from the reaction mixture in a solvent selected from the group consisting of esters, ketones, alcohols or mixtures thereof by slurrying or recrystallization.
The esters may be selected form the group consisting of ethyl acetate, propyl acetate, butyl acetate and the like.
The ketones may be selected form the group consisting of acetone, methyl ethyl ketone and the like. The alcohols may be selected from the group consisting of methanol, ethanol, propanol, isopropanol and the like.
In one embodiment the compound of formula I is isolated from the reaction mixture by slurrying in ethyl acetate. In one embodiment the compound of formula I is isolated from the reaction mixture by slurrying in methyl ethyl ketone.
In one embodiment the compound of formula I is isolated from the reaction mixture by recrystallization in methyl ethyl ketone.
In one embodiment the present invention provides a process for purification of vildagliptin, compound of formula I by a process comprising recrystallizing in an alcoholic solvent system.
In one embodiment the present invention provides a process for purification of vildagliptin, compound of formula I by a process comprising recrystallizing in isopropyl alcohol.
In one embodiment, the present invention provides vildagliptin obtained by the processes herein described, having purity more than about 99.6% as measured by High Performance Liquid Chromatography (HPLC).
In one embodiment, the present invention provides vildagliptin having compound of formula IV less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC.
In one embodiment, the present invention provides vildagliptin having compound of formula III less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC. In one embodiment, the present invention provides vildagliptin having compound of formula II less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC.
In one embodiment, the present invention provides vildagliptin having impurity D less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC.
Figure imgf000012_0001
Impurity D
In one embodiment, the present invention provides vildagliptin having impurity E or its isomer or its salt less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC.
Figure imgf000012_0002
Impurity E
In one embodiment, the present invention provides vildagliptin having impurity F or its isomer or its salt less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC.
Figure imgf000012_0003
Impurity F
In one embodiment, the present invention provides S-vildagliptin having R-vildagliptin impurity is present less than 0.15% w/w relative to the amount of S-vildagliptin as determined by chiral HPLC.
Figure imgf000013_0001
R-vildagliptin
In one embodiment, the present invention provides compound of formula III and/or vildagliptin free of impurity G or its isomer or its salt as determined by HPLC.
Figure imgf000013_0002
Impurity G
In one embodiment, the present invention provides compound of formula IV, compound of formula III, and/or vildagliptin free of impurity H or its isomer or its salt as determined by HPLC.
Figure imgf000013_0003
Impurity H
In one embodiment, the present invention provides vildagliptin, where is one or more of compounds of formula II, III, IV, impurity D, impurity E or impurity F are present less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC and R-vildagliptin is present less than 0.15% w/w relative to the amount of vildagliptin as determined by chiral- HPLC. In one embodiment, the present invention provides vildagliptin, having compound of formula III (genotoxic impurity) below detection limit, preferably below 15 parts per million (ppm).
In one embodiment, the present invention provides vildagliptin, having compound of formula IV (genotoxic impurity) below detection limit, preferably below 15 parts per million (ppm). In one embodiment the present invention provides vildagliptin, compound of formula I having bulk density of 0.54 g/cc.
In yet another embodiment, the present invention provides pharmaceutical compositions comprising vildagliptin obtained by the processes herein described, having a D90 particle size of about 375 microns, D50 particle size of about 207 microns and D10 particle size of about 37 microns.
In yet another embodiment, the present invention provides pharmaceutical compositions comprising micronized vildagliptin obtained by the processes herein described, having a D90 particle size of about 78 microns, D50 particle size of about 17 microns and Dio particle size of about 4 microns. In one embodiment the present invention provides a process for the preparation of a compound of Formula IV,
Figure imgf000014_0001
Formula IV comprising: a) reacting a compound of Formula VI
Figure imgf000014_0002
Formula VI with a compound of formula V,
Figure imgf000015_0001
Formula V in the presence of an ester, halogenated hydrocarbons, ether solvent to form a compound of , Formula IV;
The ester solvent may be selected from the group consisting of methyl acetate, ethyl acetate, n- butyl acetate, isobutyl acetate, sec-butyl acetate, isopropyl acetate and the like and mixtures thereof.
The halogenated hydrocarbons solvent may be selected from methylene chloride (MDC), ethylene chloride (EDC) and like. Ether solvent may be selected from tetrahydrofuran, tetrahydropyran and the like.
While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
EXAMPLES
Example 1: Preparation of (S)-l-(2-chloroacetyl) pyrrolidine-2-carboxamide, compound of Formula IV.
In a clean round bottom flask, lOOgm L-prolinamide, 1800ml acetonitrile and 290.16gm K2C03 were charged. The reaction mass was stirred, cooled to about 10-20°C and 108.8gm of chloroacetyl chloride was added. Temperature of reaction mass was raised to about RT, stirred for about one hour, filtered, washed with acetonitrile and concentrated under vacuum. 300ml ethyl acetate was added to reaction mass, stirred at about 50-55 °C, cooled to about 0-5 °C and stirred for about 1-2 hour. The reaction mass was filtered, washed with ethyl acetate and dried under vacuum and product isolated as a solid 130-140gm. (Yield: 77- 85%; HPLC purity >97%). Impurity H is less than 0.2% w/w relative to the amount of compound of formula IV as determined by HPLC.
Example 2: Preparation of (S)-l-(2-chloroacetyl) pyrrolidine-2-carboxamide, compound of Formula IV. In a clean round bottom flask, lOOgm L-prolinamide, 1000ml MDC and 290.16gm K2C03 were charged. The reaction mass was stirred, cooled to about 10-20°C and 108.8gm of chloroacetyl chloride was added. Temperature of reaction mass was raised to about RT, stirred for about one hour, filtered, washed with MDC and concentrated under vacuum. 300ml ethyl acetate was added to reaction mass, stirred at about 50-55 °C, cooled to about 0-5 °C. The reaction mass was filtered, washed with ethyl acetate and dried under vacuum and product isolated as a solid lOOgm. (HPLC purity >97%)
Example 3: Preparation of (S)-l-(2-chloroaeetyl) pyrrolidihe-2-carboxamide, compound of Formula IV.
In a clean round bottom flask, 1 OOgm L-prolinamide, 1500ml acetonitrile and 93.39gm sodium acetate were charged. The reaction mass was stirred, cooled to about 10-15°C and 108.8gm of chloroacetyl chloride was added. Temperature of reaction mass was raised to about RT, stirred for about one hour, filtered, washed with acetonitrile and concentrated under vacuum. Ethyl acetate was added to reaction mass, stirred and cooled to about 0-5 °C. The reaction mass was filtered, washed with ethyl acetate and dried under vacuum and product isolated as a solid lOOgm. (HPLC purity >97%)
Example 4: Preparation of (S)-l-(2-chIoroacetyl) pyrroUdine-2-carboxamide, compound of Formula IV. In a clean round bottom flask, lOOgm L-prolinamide, 1000ml THF and 166gm sodium.2-ethyl hexanoate were charged. The reaction mass was stirred, cooled to about 10-15°C and 108.8gm of chloroacetyl chloride was added. Temperature of reaction mass was raised to about T, stirred for about one hour and cooled to about 0-5 °C. The reaction mass was filtered, washed with THF and dried under vacuum and product isolated as a solid 135gm. (HPLC purity >97%) Example 5: Preparation of (S)-l-(2-chloroacetyl) pyrrolidine-2-carbonitrile, compound of Formula III.
In a clean round bottom flask, lOOgm compound IV, 3000ml ethyl acetate and phosphorous oxychloride were charged and temperature of reaction mass was raised to about 80-85°C. The reaction mass was cooled to about 5-10°C and water was added. Aqueous layer was extracted with ethyl acetate and pH was adjusted to about 7-8 by NaOH solution. Ethyl acetate layer was concentrated under vacuum to get residue and IPA and methyl tert butyl ether was added to residue. The precipitated solid was stirred for about 2 hours at about 0-5°C, filtered, washed with cold methyl tert butyl ether and dried under vacuum and product isolated as a solid 58-62gm (Yield 65-68%; HPLC purity > 99%). Example 6: Preparation of (S)-l-(2-chloroacetyI) pyrrolidine-2-carbonitrile, compound of Formula III.
In a clean round bottom flask, lOOgm compound IV, 1200ml ethyl acetate and 76.6gm DMF were charged and reaction mass was cooled to about 15°C. Phosphorous oxychloride was added to the reaction mass, stirred for about 90 minutes, cooled to about 5-10°C and water was added. Aqueous layer was extracted with ethyl acetate and pH was adjusted to about 7-8 by K2C03 solution. Ethyl acetate layer was concentrated under vacuum to get residue and methyl tert butyl ether was added to residue. The precipitated solid was stirred at about 0-5°C for about 2 hours, filtered, washed with cold methyl tert-butyl ether and dried under vacuum and product isolated as a solid 58-62gm. (Yield 65-68%; HPLC purity > 98% and other isomer less than 0.15%). Impurity G is less than 0.2% w/w relative to the amount of compound of formula III as determined by HPLC.
Example 7: Preparation of (S)-l-(2-chloroacetyl) pyrrolidine-2-carbonitriIe, compound of Formula III.
In a clean round bottom flask, lOOgm compound IV, 500ml diethylformamide (DEF) were charged. The reaction mass was cooled to 15°C. Phosphorus oxychloride was added through addition funnel at 1 -20°C and the reaction mass was stirred for 90 min. The reaction mass was cooled to 5-10°C. The reaction mass was quenched by adding water. The aqueous layer was separated and extracted with ethyl acetate. The pH of ethyl acetate layer was adjusted the pH to. -7-8 by using potassium carbonate solution. The aqueous layer was separated. The ethyl acetate layer was concentrated under vacuum (40-45°C). The residue was degassed. Methyl tert butyl ether was charged to the residue. The precipitated solid was stirred at 0-5°C for 120 min. The solid was filtered and washed with cold methyl tert butyl ether and suck dried. The solid was dried under vacuum at 30-35°C. 58-62gm of solid was obtained (Yield 65-68%, HPLC purity > 98% and other isomer less than Q.15%).
Example 8: Preparation of (S)-l-(2-chloroacetyl) pyrrolidine-2-carbonitrile, compound of Formula III.
In a clean round bottom flask, lOOgm compound IV, 1200 ml of ethyl acetate and 76.6g diethylformamide (DEF) were charged. The reaction mass was cooled to 15°C. Phosphorus oxychloride was added through addition funnel at 15-20°C and the reaction mass was stirred for 90 min. The reaction mass was cooled to 5-i0°C. The reaction mass was cooled to 5-10°C. The reaction mass was quenched by adding water. The aqueous layer was separated and extracted with ethyl acetate. The ethyl acetate layers were combined and adjusted the pH to -7-8 by using potassium carbonate solution. The aqueous layer was separated. The ethyl acetate layer was concentrated under vacuum (40-45°C). The residue was degassed. Methyl tert butyl ether was charged to the residue. The precipitated solid was stirred at 0-5°C for 120 min. The solid was filtered and washed with cold methyl tert butyl ether and suck dried. The solid was dried under vacuum at 30-35°C. 58-62gm of solid was obtained (Yield 65-68%, HPLC purity > 98% and other isomer less than 0.15%).
Example 9: Preparation of (S)-l-(2-chloroacetyl) pyrrolidine-2-carbonitrile, compound of Formula III. In a clean round bottom flask, lOOgm compound IV and 1200 ml of MDC were charged. DMF (76.6gm) was charged in the flask. The reaction mass was cooled to 15°C. Phosphorus oxychloride was added through addition funnel at 15-20°C and the reaction mass was stirred for 90 min. Cool the reaction mass to 5-10°C. The reaction mass was cooled to 5-10°C. The reaction mass was cooled to 5-10°C. The reaction mass was quenched by adding water. The aqueous layer was separated and extracted with MDC. The MDC layers were combined and the pH adjusted to -7-8 by using potassium carbonate solution. The aqueous layer was separated. The MDC layer was concentrated under vacuum (40-45°C). The residue was degassed. Methyl tert butyl ether was charged to the residue. The precipitated solid was stirred at 0-5°C for .120 min. The solid was filtered and washed with cold methyl tert butyl ether and suck dried. The solid was dried under vacuum at 30-35°C. 58-62gm of solid was obtained (Yield 65-68%, HPLC purity > 98% and other isomer less than 0.15%).
Example 10: Preparation of (S)-l-(2-chloroacetyl) pyrrolidine-2-carbonitrile, compound of Formula III.
In a clean round bottom flask, lOOgm compound IV and 500ml of DMF were charged. The reaction mass was cooled to 15°C. A solution of cyanuric chloride (142.8g) in THF was added „ through addition funnel at 5-10°C. After complete addition, the temperature was raised to 10- 15°C) and stirred for 90 minutes. The reaction mass was quenched in to cold water and pH was adjusted to 6-7 using potassium carbonate. The reaction mass was extracted with MDC. The MDC layer was washed with water. The MDC layer was concentrated under vacuum (40-45°C). The residue was degassed. The residue was degassed. Methyl tert butyl ether was charged to the residue. The precipitated solid was stirred at 0-5°C for 120 min. The solid was filtered and washed with cold methyl tert butyl ether and suck dried. The solid was dried under vacuum at 30-35°C. 22-35gm of solid was obtained (Yield 25-38%, HPLC purity > 99% and other isomer less than 0.15%). Example 11: Preparation of (S)-l-(2-chloroacetyI) pyrrolidine-2-carbonitrile, compound of Formula III.
In a clean round bottom flask, thiphosgene (lOOgm) and 100ml of MDC were charged. The reaction mass was cooled to 5-10°C. A solution of DMF (75gm) in MDC (100ml) was added. After complete addition, the temperature was raised to 15-20°C. The reaction mass was stirred for 30 minutes. The reaction mass was cooled to 5-10°C. The compound of IV was added in one lot. The reaction mass was stirred at 5-10°C and stirred for 90 minutes. The reaction mass was quenched by adding' water. The MDC layer was separated and pH was adjusted to 6-7 by using potassium carbonate. The MDC layer was concentrated under vacuum (40-45°C). The residue was degassed. The residue was degassed. Methyl tert butyl ether was charged to the residue. The precipitated solid was stirred at 0-5°C for 120 min. The solid was filtered and washed with cold methyl tert-butyl ether and suck dried. The solid was dried under vacuum at 30-35°C. 45-50gm of solid was obtained (Yield 50-55%, HPLC purity > 97%).
Example 12: Preparation of vildagliptin, compound of Formula I. In a clean round bottom flask, (lOOgm) of l-amino-3-adamantol in 1000ml of acetonitrile were charged. 239.8gm of potassium carbonate was charged to the above flask. The reaction mass was heated to 82-85°C. The compound of formula III (4x25gm), was charged after 60-90 min intervals. After completion of reaction, the reaction mass was cooled to 65-70°C. The reaction mass was filtered and the solid was washed with 500ml acetonitrile and suck dried. The acetonitrile was distilled out from filtrate under vacuum at 50-55°C. Ethyl acetate was charged to the residue and the slurry stirred at 50-55°C for 30-45 minutes. The slurry was cooled to 20-30°C and stirred for 60-90 minutes. The solid was filtered and washed with ethyl acetate and suck dried. The wet cake was suspended in IPA and heated to 80-85°C to get a clear solution. The clear solution was charcoalised and filtered through hyflo. The filtrate was distilled out under vacuum to get final volume to 5Volume. The reaction mass was cooled to -5 to 5°C and stirred for 60-90 minutes. The solid was filtered and washed with IPA and suck dried. The solid was dried under vacuum at 50-55°C. 105 to 120gm of solid was obtained (yield 59-68%, HPLC purity >98%) Example 13: Preparation of vildagliptin, compound of Formula I.
In a clean round bottom flask, (lOOgm) of l-amino-3-adamantol in 1000ml of acetonitrile were charged. 239.8gm of potassium carbonate was charged to the above flask. The reaction mass was heated to 82-85°C. The compound of formula III (4x25gm), was charged after 60-90 minutes intervals. After completion of reaction, the reaction mass was cooled to 65-70°C. The reaction mass was filtered and the solid was washed with 500ml acetonitrile and suck dried. The acetonitrile was distilled out .from filtrate under vacuum at 50-55°C. Methyl ethyl ketone was charged to the residue and the slurry stirred at 50-55°C for 30-45 minutes. The slurry was cooled to 20-30°C and stirred for 60-90 minutes. The solid was filtered and washed with methyl ethyl ketone and suck dried. The wet cake was suspended in IPA and heated to 80-85 °C to get a clear solution. The clear solution was charcoalised and filtered through hyflo. The filtrate was {distilled out under vacuum to get final volume to 5Volume. The reaction mass was cooled to -5 to 5°C and stirred for 60-90 minutes. The solid was filtered and washed with IPA and suck dried. The solid was dried under vacuum at 50-55°C. 105 to 120gm of solid was obtained (yield 59-68%, HPLC purity >98%)
Example 14: Purification of Vildagliptin, compound of Formula I.
In a clean round bottom flask lOOgm of vildagliptin and 450ml IPA were charged. The reaction mass was heated to 80-85°C to get clear solution. The clear solution was stirred for 30-45 min. The reaction mass was cooled to 70-75°C. The clear solution was filtered through micron filter; and the micron filter was washed with IPA (50ml). IPA was distilled under vacuum to get final volume 350ml. The reaction mass was cooled to -5 to 5°C and -stirred for 60-90 minutes. The solid obtained was filtered and washed with IPA (50ml) and suck dried. The solid was dried under vacuum at 50-55°C. 88-92gm of solid was obtained (Yield 88-92%, HPLC purity >99.6%). R-vildagliptin is less than 0.01%, impurity D is less than 0.03%, impurity E is less than 0.01%, compound of formula III (genotoxic impurity) is below detection limit, compound of formula IV (genotoxic impurity) is below detection limit, bulk, density of 0.54 g/cc, Particle size distribution: dio about 34 microns, d5o about 177 microns and dgo about 318 microns.

Claims

We claim:
1) A process for the preparation of vildagliptin, a compound of formula I,
Figure imgf000022_0001
Formula I
comprising:
a) reacting a compound of formula VI
Figure imgf000022_0002
Formula VI
with a compound of formula V,
Figure imgf000022_0003
Formula V
in the presence of a nitrile solvent to form a compound of formula IV;
Figure imgf000022_0004
Formula IV
b) reacting the compound of formula IV with a dehydrating agent to form a compound of formula III,
Figure imgf000023_0001
Formula III c) reacting the compound of formula III with a compound of formula II,
Figure imgf000023_0002
Formula II to form a compound of formula I.
2) The process as claimed in claim 1, wherein in step a) the nitrile solvent is acetonitrile.
3) The process as claimed in claim 1 , wherein the step a) is carried out in presence of a base.
4) The process as claimed in claim 3, wherein the base is potassium carbonate. 5) The process as claimed in claim 1, wherein the step b) is .carried out in presence of a dehydrating agent selected from group consisting of POCl3, Vilsmeier reagent, Gold reagent, mixture of D F and triphosgene, mixture of DMF and SOCl2, mixture of DMF and oxalyl chloride.
6) The process as claimed in claim 1, wherein in step b) reaction of compound of formula IV with a dehydrating agent is carried out at 0° C to about 20° C.
7) The process as claimed- in claim 1, wherein the compound of formula III and/or compound of formula IV is isolated from the reaction mixture.
8) The process as claimed in claim 7, wherein the compound of formula III and/or compound of formula IV is isolated by slurrying the reaction mixture with an organic solvent. 9) The process as claimed in claim 8, wherein the organic solvent is ether solvent, alcohol solvent or mixtures of ether solvent and alcohol solvent.
10) The process as claimed in claim 1, wherein in step c) reaction of compound of formula IIII with compound of formula II is carried out at about 40° C to about 80° C. 11) The process as claimed in claim 1 , wherein vildagliptin a compound of formula I, obtained has impurity G and impurity H less than 0.15% w/w relative to the amount of vildagliptin as determined by HPLC.
PCT/IN2013/000787 2012-12-26 2013-12-23 Improved process for preparation of vildagliptin WO2014102815A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3622MU2012 2012-12-26
IN3622/MUM/2012 2012-12-26

Publications (1)

Publication Number Publication Date
WO2014102815A1 true WO2014102815A1 (en) 2014-07-03

Family

ID=51020007

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000787 WO2014102815A1 (en) 2012-12-26 2013-12-23 Improved process for preparation of vildagliptin

Country Status (1)

Country Link
WO (1) WO2014102815A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104262227A (en) * 2014-09-16 2015-01-07 东北制药集团股份有限公司 Preparation method of (S)-1-(2-chloracetyl)pyrrolidine-2-carbonitrile
CN104387309A (en) * 2014-11-19 2015-03-04 苏州乔纳森新材料科技有限公司 Synthetic method of alpha-glucosaccharase inhibitor intermediate
CN104945299A (en) * 2015-05-28 2015-09-30 烟台万润药业有限公司 Efficient synthesis method of vildagliptin
CN106187849A (en) * 2016-07-05 2016-12-07 天津民祥生物医药股份有限公司 A kind of purification process of (S) 1 (2 chloracetyl chloride) 2 itrile group pyrrolidine crude product
CN107793341A (en) * 2016-09-06 2018-03-13 江苏天士力帝益药业有限公司 A kind of preparation method of vildagliptin intermediate
CN109776372A (en) * 2019-01-18 2019-05-21 珠海联邦制药股份有限公司 Related substance of vildagliptin and preparation method thereof
CN110940759A (en) * 2019-12-23 2020-03-31 河北科技大学 HPLC (high performance liquid chromatography) detection method of vildagliptin intermediate-5
WO2022003405A1 (en) 2020-07-03 2022-01-06 Savoi Guilherme One-pot process to obtain a pyrrolidine-2-carbonitrile intermediate compound and industrial scale telescopic process to prepare (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptin) using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011012322A2 (en) * 2009-07-31 2011-02-03 Krka, D.D., Novo Mesto Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms
JP2012197291A (en) * 2006-11-29 2012-10-18 Mitsubishi Tanabe Pharma Corp Method for producing n-(n'-substituted glycyl)-2-cyanopyrrolidine derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012197291A (en) * 2006-11-29 2012-10-18 Mitsubishi Tanabe Pharma Corp Method for producing n-(n'-substituted glycyl)-2-cyanopyrrolidine derivative
WO2011012322A2 (en) * 2009-07-31 2011-02-03 Krka, D.D., Novo Mesto Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104262227A (en) * 2014-09-16 2015-01-07 东北制药集团股份有限公司 Preparation method of (S)-1-(2-chloracetyl)pyrrolidine-2-carbonitrile
CN104262227B (en) * 2014-09-16 2018-09-18 东北制药集团股份有限公司 A method of preparing (S) -1- (2- chloracetyls) pyrrolidines -2- formonitrile HCNs
CN104387309A (en) * 2014-11-19 2015-03-04 苏州乔纳森新材料科技有限公司 Synthetic method of alpha-glucosaccharase inhibitor intermediate
CN104945299A (en) * 2015-05-28 2015-09-30 烟台万润药业有限公司 Efficient synthesis method of vildagliptin
CN104945299B (en) * 2015-05-28 2017-03-15 烟台万润药业有限公司 A kind of high-efficiency synthesis method of vildagliptin
CN106187849A (en) * 2016-07-05 2016-12-07 天津民祥生物医药股份有限公司 A kind of purification process of (S) 1 (2 chloracetyl chloride) 2 itrile group pyrrolidine crude product
CN107793341A (en) * 2016-09-06 2018-03-13 江苏天士力帝益药业有限公司 A kind of preparation method of vildagliptin intermediate
CN109776372A (en) * 2019-01-18 2019-05-21 珠海联邦制药股份有限公司 Related substance of vildagliptin and preparation method thereof
CN110940759A (en) * 2019-12-23 2020-03-31 河北科技大学 HPLC (high performance liquid chromatography) detection method of vildagliptin intermediate-5
WO2022003405A1 (en) 2020-07-03 2022-01-06 Savoi Guilherme One-pot process to obtain a pyrrolidine-2-carbonitrile intermediate compound and industrial scale telescopic process to prepare (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptin) using same

Similar Documents

Publication Publication Date Title
WO2014102815A1 (en) Improved process for preparation of vildagliptin
JP7008750B2 (en) LFA-1 inhibitor and its polymorphism
JP6371768B2 (en) Process for producing indacaterol and pharmaceutically acceptable salts thereof
US20100016590A1 (en) Nilotinib intermediates and preparation thereof
KR20210144916A (en) High-purity quinoline derivative and method for manufacturing same
WO2012042534A2 (en) Processes for the preparation of r-sitagliptin and intermediates thereof
US8158798B2 (en) Coupling process for preparing quinolone intermediates
RU2621725C2 (en) Method for preparation of 1-([1,3]dioxolan-4-ylmethyl)-1h-pyrazol-3-ylamine
WO2015037016A2 (en) An improved process for the preparation of ticagrelor and intermediates thereof
WO2015145467A1 (en) An improved process for preparing vildagliptin
US11623933B2 (en) Process for the preparation of sodium (2R,5S,13AR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl) carbamoyl)-2,3,4,5,7,9,13,13A-octahydro-2,5-Methanopyrido[1 ′,2′:4,5]pyrazino[2,1 -b] [1,3] oxazepin-8-olate and its polymorphic form
WO2017060885A1 (en) An improved process for preparation of atorvastatin or pharmaceutically acceptable salts thereof
EP1999106B1 (en) A hydride reduction process for preparing quinolone intermediates
WO2014155259A2 (en) Process for the preparation of rivaroxaban
KR20150056541A (en) Process for the preparation of sitagliptin and intermediate compounds
WO2012004811A1 (en) Process for the preparation of 5-substsituted indole derivative
KR20080019151A (en) Process for preparing carbostyril compounds
AU2006307471A1 (en) An improved process for preparation of irbesartan
CN102971297B (en) Method for preparing an intermediate of pitavastatin or of the salt thereof
CZ304984B6 (en) Enhanced process for preparing and novel intermediates of elvitegravir synthesis
KR20120129317A (en) Manufacturing Method Of Hetero Cyclic Compound
KR101557702B1 (en) Method for the preparation of Mitiglinide Calcium Dihydrate
US8937053B2 (en) Process for the preparation of prasugrel and several novel crystalline forms of prasugrel hydrochloride
JP2018502858A (en) Method for producing forodesin
US9499491B2 (en) One pot process for the preparation of telmisartan

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13867156

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13867156

Country of ref document: EP

Kind code of ref document: A1